PIMS-E, a subsidiary of PureIMS, completes Dosing in Phase 1 Clinical Trial of Epinephrine Cyclops™, a Dry Powder Inhalation Device for Early Intervention in Allergic Reactions and Anaphylaxis

Month: August 2020

PIMS-E, a subsidiary of PureIMS, completes Dosing in Phase 1 Clinical Trial of Epinephrine Cyclops™, a Dry Powder Inhalation Device for Early Intervention in Allergic Reactions and Anaphylaxis

Delivery via inhaler could dramatically expand Epinephrine’s clinical utility for emergency self-administration to prevent worsening of early symptoms of anaphylaxis Roden, The Netherlands — August 4th, 2020 — PIMS-E, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for allergic reactions and anaphylaxis, announced the completion of the dosing of 10 subjects in […]